Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer

Head and Neck

Volumn 33, Issue 3, 2011, Pages 375-382

  Knegjens, Joost L ^a   Hauptmann, Michael ^a   Pameijer, Frank A ^a   Balm, Alfons J ^a,b   Hoebers, Frank J ^a   De Bois, Josien A ^a   Kaanders, Johannes H ^c   Van Herpen, Carla M ^c   Verhoef, Cornelia G ^d   Wijers, Oda B ^e   Wiggenraad, Ruud G ^f   Buter, Jan ^g   Rasch, Coen R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Arnhems Radiotherapeutisch Instituut   (Netherlands)

^e Radiotherapy Institute Friesland   (Netherlands)

^f MEDICAL CENTER HAAGLANDEN   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemoradiation; head and neck cancer; prognostic factor; radiotherapy; tumor volume

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 79951716171     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21459     Document Type: Article

References (43)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK,. Head and neck cancer. N Engl J Med 1993; 328: 184-194.
2. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
3. Allal AS, Bieri S, Miralbell R, et al. Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone. Ann Oncol 1997; 8: 681-684. (Pubitemid 27372167)
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76. (Pubitemid 41095116)
5. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 23-28. (Pubitemid 34465803)
6. El Sayed S, Nelson N,. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-847. (Pubitemid 26085529)
7. Sobin LH, Wittekind Ch,. UICC TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss Press, 2002.
8. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J III, Wazer DE,. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995; 32: 635-641.
9. Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C,. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007; 46: 386-394. (Pubitemid 46625041)
10. van den Broek GB, Rasch CR, Pameijer FA, et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101: 1809-1817. (Pubitemid 39314744)
11. Brenner DJ,. Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys 1993; 26: 171-179. (Pubitemid 23137904)
12. Bentzen SM, Thames HD,. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 1996; 36: 247-251. (Pubitemid 26314173)
13. Dubben HH, Thames HD, Beck-Bornholdt HP,. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998; 47: 167-174. (Pubitemid 28275927)
14. Hermans R, Op de beeck K, Van den Bogaert W, et al. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2001; 50: 37-45.
15. Kraas JR, Underhill TE, D'Agostino RB Jr, Williams DW III, Cox JA, Greven KM,. Quantitative analysis from CT is prognostic for local control of supraglottic carcinoma. Head Neck 2001; 23: 1031-1036. (Pubitemid 33107932)
16. Pameijer FA, Mancuso AA, Mendenhall WM, et al. Evaluation of pretreatment computed tomography as a predictor of local control in T1/T2 pyriform sinus carcinoma treated with definitive radiotherapy. Head Neck 1998; 20: 159-168. (Pubitemid 28106229)
17. Wolters U, Wolf T, Stützer H, Schröder T,. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996; 77: 217-222. (Pubitemid 26254509)
18. Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB,. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 1992; 14: 364-371.
19. Balm AJ, Rasch CR, Schornagel JH, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26: 485-493. (Pubitemid 38702635)
20. Rasch CRN, Salverda GJ, Schornagel JH, et al. Plenary 2: intra-arterial versus intravenous chemoradiation for advanced head and neck cancer, early results of a multi-institutional trial. Int J Radiat Oncol Biol Phys 2006; 66 (3 Suppl): S1-2.
21. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-940. (Pubitemid 37159288)
22. Hoebers FJ, Heemsbergen W, Balm AJ, van Zanten M, Schornagel JH, Rasch CR,. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol 2007; 85: 42-47. (Pubitemid 47570059)
23. Narayan K, Fisher R, Bernshaw D,. Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy. Int J Gynecol Cancer 2006; 16: 623-630.
24. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S,. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006; 64: 449-454. (Pubitemid 43083431)
25. Doweck I, Denys D, Robbins KT,. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope 2002; 112: 1742-1749.
26. Chen SW, Yang SN, Liang JA, Lin FJ, Tsai MH,. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck 2009; 31: 709-716.
27. Tsou YA, Hua JH, Lin MH, Tsai MH,. Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer-does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec 2006; 68: 206-212.
28. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-146. (Pubitemid 28109172)
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
30. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715. (Pubitemid 350005152)
31. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004; 10: 3745-3754. (Pubitemid 38697608)
32. Salesiotis AN, Cullen KJ,. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000; 12: 229-239. (Pubitemid 32042736)
33. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-598. (Pubitemid 46630421)
34. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747. (Pubitemid 46622040)
35. Hoebers FJ, Pluim D, Verheij M, et al. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 2006; 119: 750-756. (Pubitemid 44051437)
36. Hoogsteen IJ, Marres HA, Bussink J, van der Kogel AJ, Kaanders JH,. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 2007; 29: 591-604. (Pubitemid 47324777)
37. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML, Srivastava K,. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume. Jpn J Clin Oncol 2006; 36: 537-546. (Pubitemid 44593895)
38. Pameijer FA, Balm AJ, Hilgers FJ, Muller SH,. Variability of tumor volumes in T3-staged head and neck tumors. Head Neck 1997; 19: 6-13. (Pubitemid 26425083)
39. Rudat V, Dietz A, Schramm O, et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999; 53: 119-125.
40. Rasch C, Keus R, Pameijer FA, et al. The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1997; 39: 841-848. (Pubitemid 27486072)
41. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233: 93-100. (Pubitemid 39280962)
42. Cooper JS, Mukherji SK, Toledano AY, et al. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). Int J Radiat Oncol Biol Phys 2007; 67: 972-975.
43. Preda L, Lovati E, Chiesa F, et al. Measurement by multidetector CT scan of the volume of hypopharyngeal and laryngeal tumours: accuracy and reproducibility. Eur Radiol 2007; 17: 2096-2102. (Pubitemid 47097468)